FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer

The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.
Summit Therapeutics announced on 15 November 2026 that the US Food and Drug Administration had declined to approve ivonescimab in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted treatment, issuing a Complete Response Letter in response to the company's biologics licence application.
The decision followed review of the HARMONi clinical trial, which showed improvement in progression-free survival without establishing a statistically significant overall-survival benefit in the submitted analysis; ivonescimab is an investigational PD-1 × VEGF bispecific antibody developed by Akeso and licensed to Summit, and the regulatory setback does not represent a clinical hold or permanent discontinuation of the programme.
Field | Content |
Article Type | Approvals |
Regulatory Event | FDA Complete Response Letter |
Regulatory Outcome | Approval declined |
Company | Summit Therapeutics |
Originating Developer | Akeso |
Investigational Medicine | Ivonescimab |
Drug Modality | Bispecific antibody |
Molecular Targets | PD-1 and VEGF |
Regulatory Authority | US Food and Drug Administration |
Announcement Date | 15 November 2026 |
Regulatory Submission | Biologics licence application |
Proposed Treatment | Ivonescimab plus platinum-containing chemotherapy |
Therapeutic Area | Oncology |
Cancer Type | Non-small cell lung cancer |
Molecular Subtype | EGFR-mutated |
Proposed Patient Population | Patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted therapy |
Treatment Setting | After prior EGFR-targeted treatment |
Supporting Clinical Trial | HARMONi |
Progression-Free Survival Finding | Benefit demonstrated |
Overall Survival Finding | Statistically significant benefit not established in the submitted analysis |
Regulatory Concern | Overall-survival evidence did not establish the required benefit |
US Marketing Approval Granted | No |
Clinical Hold Imposed | Not reported |
Programme Permanently Terminated | Not reported |
Commercial Launch Authorised | No |
What Happened | The FDA issued a Complete Response Letter declining Summit's application for ivonescimab in EGFR-mutated lung cancer. |
Why It Matters | The decision creates a significant regulatory obstacle for a high-profile bispecific antibody programme in lung cancer. |
Clinical Significance | The regulatory outcome highlights the importance of overall-survival evidence alongside progression-free survival in oncology development. |
Strategic Significance | The setback affects Summit's US development and commercialisation plans for ivonescimab. |
Regulatory Clarification | A Complete Response Letter is not an approval and does not necessarily end future development or resubmission. |
Key Takeaway | Ivonescimab has not received FDA approval for the submitted EGFR-mutated lung cancer indication. |
What to Watch | Summit's response to the FDA, additional survival analyses, potential regulatory discussions and any future resubmission. |
Primary Source | Summit Therapeutics |
Primary Source URL | https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application-2026.pdf |
Submitted Source | Reuters |
Submitted Source URL | https://www.reuters.com/legal/litigation/us-fda-declines-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-2026-11-15/ |
Relevant Date | 15 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments